# The rhetoric marshalled by the conservative groups to oppose President Donald Trump’s drug pricing policy aligns with that used by PhRMA itself.

*biotech · news · 2026-02-24 · Washington Examiner*

## Key points

- PhRMA-funded conservative groups' rhetoric opposing Trump’s drug pricing plan exactly matches PhRMA’s messaging.
- Several PhRMA-funded groups received over $1 million between 2019 and 2024 from the trade association.
- Some coverage of these groups' opposition to Trump’s policy omitted their pharmaceutical industry funding.
- PhRMA blames pharmacy benefit managers and 340B abuses for high drug prices, arguments echoed by its funded groups.
- Industry funding enables PhRMA's positions to gain significant traction in national policy discussions.

**Companies:** PhRMA
**Countries:** United States, China

[Read the full story on Washington Examiner](https://www.washingtonexaminer.com/news/investigations/4468331/conservative-opposition-trump-drug-plan-bankrolled-pharmaceutical-industry/)

---

Canonical: https://newsio.io/n/1b8d7cbe-3944-4fe8-8575-0b2ec9e43eef/the-rhetoric-marshalled-by-the-conservative-groups-to-oppose-president-donald-tr
Summarized by Newsio from Washington Examiner. https://newsio.io/how-it-works